We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
3 peer-reviewed studies
What the evidence says
Most Wormwood studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2006–2010 with a typical study size of 40 participants.
Based on 3 studies · 2 RCTs · 60 total participants
Confidence
LowBy outcome
Newest study from 2010
Wormwood contains the toxic monoterpene thujone, the agent implicated in the neurological syndrome 'absinthism' described after chronic absinthe abuse.
Lachenmeier DW, Walch SG, Padosch SA, Kröner LU. · Crit Rev Food Sci Nutr (2006)
In 40 Crohn's patients, a wormwood-containing blend allowed steroid tapering with near-complete symptom remission in 65% by week 8, versus none on placebo — a small but striking steroid-sparing signal.
Omer B, Krebs S, Omer H, Noor TO. · Phytomedicine (2007)
Adding wormwood to standard Crohn's therapy lowered serum TNF-alpha from 24.5 to 8.0 pg/ml over six weeks and improved disease activity, supporting an anti-inflammatory mechanism.
Krebs S, Omer TN, Omer B. · Phytomedicine (2010)